Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Postoperative Complications 1Osteoarthritis 1Insulin Resistance 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 95Cisplatin 72Capecitabine 39Oxaliplatin 38durvalumab 29Fluorouracil 27pembrolizumab 26Leucovorin 23S 1 (combination) 19Nivolumab 14Irinotecan 14lenvatinib 13Bevacizumab 13tremelimumab 10130-nm albumin-bound paclitaxel 9apatinib 8Trastuzumab 7Injections 7Immune Checkpoint Inhibitors 7Docetaxel 7Albumin-Bound Paclitaxel 7Paclitaxel 6Drug Therapy 6titanium silicide 5surufatinib 5irinotecan sucrosofate 5gemcitabine-oxaliplatin regimen 5envafolimab 5camrelizumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × World Health Organization oral rehydration solution × Clear all
NCT01917617 2019-02-21

Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer

Kansai Hepatobiliary Oncology Group

Phase 2 Completed
50 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡